Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis

Journal of Rheumatology

Volumn 36, Issue 10, 2009, Pages 2308-2313

  Masi, Laura ^a   Ricci, Laura ^b   Zulian, Francesco ^a,b   Del Monte, Francesca ^a   Simonini, Gabriele ^b   Capannini, Serena ^b   De Martino, Maurizio ^b   Brandi, Maria Luisa ^c   Falcini, Fernanda ^b  

^a Department of Internal Medicine ^*

^b UNIVERSITY OF FLORENCE   (Italy)

^c School of Medicine

Author keywords

Juvenile idiopathic arthritis; Marker; Methotrexate; Osteopontin

Indexed keywords

ETANERCEPT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOPONTIN;

ADD ON THERAPY; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCHOOL CHILD; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL MARKERS; CHILD; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 70450172620     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.081156     Document Type: Article

References (21)

1. Cassidy JT, Petty RE. Chronic arthritis in childhood. In: Cassidy JT, Petty RE, editors. Textbook of pediatric rheumatology. 5th ed. New York: Churchill Livingston; 2005:206-333.
2. Sodek J, Chen J, Nagata T, Kasugai S, Todescan R Jr, Li IW, Kim RH. Regulation of osteopontin expression in osteoblasts. Ann NY Acad Sci 1995;760:223-241.
3. Xu G, Sun W, He D, Wang L, Zheng W, Nie H, et al. Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism. J Rheumatol 2005;32:410-416. (Pubitemid 40381409)
4. Ohshima S, Yamaguchi N, Nishioka K, Mima T, Ishii T, Umeshita-Sasai M, et al. Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol 2002;29:2061-2067.
5. Petrow PK, Hummel KM, Schedel J, Franz JK, Klein CL, Müller-Ladner U, et al. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum 2000;43:1597-1605. (Pubitemid 30452481)
6. Gravallese EM. Osteopontin: a bridge between bone and immune system. J Clin Invest 2003;112:147-149.
7. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin - a molecule for all seasons. Q J Med 2002;95:3-13.
8. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (osteopontin): an early component of type-I (cell-mediated) immunity. Science 2000;287:860-864. (Pubitemid 30084330)
9. Muller-Ladner U, Gay RE, Gay S. Role of nuclear factor kappa B in synovial inflammation. Curr Rheumatol Rep 2002;4:201-207.
10. Yumoto K, Ishijima M, Rittling SR, Tsuji K, Tsuchiya Y, Kon S, et al. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci USA 2002;99:4556-4561. (Pubitemid 34286023)
11. Ishii T, Ohshima S, Ishida T, Mima T, Tabunoki Y, Kobayashi H, et al. Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. Biochem Biophys Res Commun 2004;316:809-815. (Pubitemid 38368024)
12. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodelling, and cell survival. J Clin Invest 2001;107:1055-1061. (Pubitemid 32422899)
13. Xu G, Nie H, Li N, Zheng W, Zhang D, Feng G, et al. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest 2005;115:1060-1067. (Pubitemid 40489411)
14. James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, Proudman SM. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J Rheumatol 2008;35:562-571.
15. Wessels JA, Kooloos WM, De Jonge R, De Vries-Bouwstra JK, Allaart CF, Linssen A, et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2006;54:2830-2839. (Pubitemid 44497761)
16. Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004;50:2750-2756. (Pubitemid 39209511)
17. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiophatic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-392. (Pubitemid 38160763)
18. Ruperto N, Murray KJ, Gerloni V, Wulfraat N, de Oliveira SK, Falcini F, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-2201. (Pubitemid 38924397)
19. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-1209.
20. Yoshitake H, Rittling SR, Denhardt DT, Noda M. Osteopontin-deficent mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci USA 1999;96:8156-8160. (Pubitemid 29328424)
21. Hunter GK, Kyle CL, Goldberg HA. Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J 1994;300:723-728.